



The 2nd
**Rare Disease Asia
Conference 2016**

17 - 19 November 2016
Hotel Pullman Bangsar,




ORGANISED BY



Participation in Healthcare Decision Making

Mr. Boon Putthipongtanachot
Chairman of Genetic LSD Foundation (Thailand)

Healthcare Insurance System in Thailand

SCHEME	 <p>Civil Servant Medical Benefit Scheme (CSMBS)</p>	 <p>Social Health Insurance (SHI)</p>	 <p>Universal Coverage (UC)</p>
Beneficiaries	Government employees & dependents coverage includes parents, spouse, and children under 18	Private sector employees	The rest of population
Population Coverage	5 million (8%)	11 Million(17%)	49 Million(75%)
Source of Funding	Government	Tri-party: employer, employee, government	Government
Management Organization	Ministry of Finance	Ministry of Labour	Ministry of Public Health
Prescription Constraint	Not limited to NLEM (National List of Essential Medicine)	NLEM only	NLEM only
Benefit package development authority	Comptroller General's Department	Medical Committee	The Subcommittee for Development of Benefit Package and Service Delivery NHSO

Current Development of HTA in Thailand

- ❑ HTA agency in Thailand namely HITAP(Health Intervention and Technology Assessment Program) under Ministry Of Public Health.
- ❑ Policy makers utilize HTA in coverage healthcare decisions :
 - ❑ Universal Health Coverage plan – benefit package (UCBP)
 - ❑ National List of Essential Medicines (NLEM)
- ❑ General perception: HTA = economic evaluation, budget impact

Utilization of HTA in coverage decisions


□ Universal Health Coverage plan – benefit package

- UHC manager: National Health Security Office (NHSO)
- Interventions: diagnosis, treatment, prevention, health promotion, rehabilitation
- Focus: safety, effectiveness, cost-effectiveness, budget impact

□ National List of Essential Medicines (NLEM)

- Executive Committee, with support from technical working groups
- National pharmaceutical benefit package
- Interventions: pharmaceuticals, vaccines and other biological products
- Focus: safety, effectiveness, cost-effectiveness, budget impact and others

UC Benefit Package development Process



Stakeholder participation

7 group of Stakeholder on Topic Nomination*




4 working groups on topic selection



***Topic Nomination**

- Each stakeholders' group can nominate 3 topic/ period.
- There are 2 submission period annually- February and August

Priority setting criteria




Health intervention assessment



Sharing Real Case on Imiglucerase

- ❖ Genetic LSD Foundation submitted Imigucerase for Gaucher through NLEM committees
- ❖ NLEM committee asked HITAP to assess the Cost –effectiveness and budget impact of Imiglucerase

Decision Process for including New Medicines into NLEM



Why Imiglucerase was listed on the NLEM

- Imiglucerase is life-saving
- Catastrophic Illness
 - The only medicine of choice and expensive
- Gaucher Disease is Rare Disease
- Not Cost-effective but low budget impact.

Budget Management Strategy



Symptomatic treatment
of Gaucher disease.

Allow patient time for
partial recovery and
better fit for next stage.

Bone marrow
transplant

Equity: enable poor patients to have access



The 2nd
**Rare Disease Asia
Conference 2016**

17 - 19 November 2016
Hotel Pullman Bangsar,

ORGANISED BY



Thank You

